MNOV: Q2 2026 revenue grew and net loss narrowed, with cash reserves supporting operations into 2027
MediciNova (MNOV) reported a revenue increase to $0.5M in Q2 2026, primarily from Mayo ALS study services, while significantly narrowing its net loss to $2.3M. Research and development expenses decreased year-over-year, and the company's $25.4M in cash reserves are projected to fund operations until …